CVS adds Eliquis, other vital drugs to formulary exclusions

Below is an excerpt from an article posted on ModernHealth.com. A link to the full article on their page appears at the end of the excerpt.

For eight years, Beth Joyner Waldron has counted on Eliquis to treat clots in her lungs and legs.

In November 2021, she received a letter from CVS Caremark telling her the pharmacy benefit manager is excluding Eliquis from its formulary next year. Receiving the letter made her emotional.

Just a year ago, her father bled to death. Joyner Waldron said he had an adverse reaction to his blood thinner.

“I nearly died from my blood clots 18 years ago and I know from my dad’s experience the treatment carries a high risk,” Joyner Waldron said. “I’ve been stable, I’ve not had any bleeds, and then I get this letter saying I have to switch meds, that obviously induces anxiety.”

She also was angry that the letter did not include information on how to appeal the decision.

As of January 1, one of the nation’s largest pharmacy benefit managers no longer covers a blood thinner that Joyner Waldron and an estimated 3 million others rely on to prevent and treat blood clots. Just five weeks before the formulary change was made, CVS’ $39 billion Caremark subsidiary sent letters to its commercial enrollees, alerting them that they would need to switch from Bristol-Myers Squibb’s Eliquis to Janssen Pharmaceuticals’ Xarelto, both anticoagulants that experts say have never been proved to be interchangeable through randomized control trials.

To read the rest of this article, please visit the site where this article originally appeared: https://www.modernhealthcare.com/patient-care/cvs-adds-more-vital-drugs-formulary-exclusions

We do our best to identify relevant and interesting news in the healthcare industry published by all sources. We encourage everyone who would like to read more than the initial excerpt provided here to access the full text via the original publisher.

Leave a Comment

Your email address will not be published. Required fields are marked *